Pharma’s Value Chain Disrupted: Can the Industry Adapt to the IRA?
The Inflation Reduction Act (IRA) represents a significant transformation within the US healthcare landscape. While focused on reducing prescription drug costs for consumers, which rose by about 31% between 2016 and 2022, the Act presents a fundamental challenge to the established operating model of pharmaceutical companies. The IRA functions as a catalyst, prompting a necessary… Read More
